Impact of non-steroidal anti-inflammatory drugs on cardiovascular risk: Is it the same in osteoarthritis and rheumatoid arthritis?

Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?

(2015) Maarten Boers   ANNALS OF THE RHEUMATIC DISEASES

The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis

(2015) Camille Roubille et al.   ANNALS OF THE RHEUMATIC DISEASES

Long-Term Frequent Use of Non-Steroidal Anti-Inflammatory Drugs Might Protect Patients with Ankylosing Spondylitis from Cardiovascular Diseases: A Nationwide Case-Control Study

(2015) Wen-Chan Tsai et al.   PLoS One

Increased Risk of Chronic Kidney Disease in Rheumatoid Arthritis Associated with Cardiovascular Complications – A National Population-Based Cohort Study

(2015) Hsien-Yi Chiu et al.   PLoS One

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation

(2014) Y Chen et al.   HEALTH TECHNOLOGY ASSESSMENT

Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study

(2014) Francisco J. de Abajo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Inadequate pain relief and large functional loss among patients with knee osteoarthritis: evidence from a prospective multinational longitudinal study of osteoarthritis real-world therapies

(2014) Philip G. Conaghan et al.   RHEUMATOLOGY

Depression and Cardiovascular Disease: An Update on How Course of Illness May Influence Risk

(2014) Jess G. Fiedorowicz   Current Psychiatry Reports

Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study

(2013) Jesper Lindhardsen et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular risk in rheumatoid arthritis: How to lower the risk?

(2013) D.F. van Breukelen-van der Stoep et al.   ATHEROSCLEROSIS

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials

(2013)   LANCET

Advice from Professional Societies: Appropriate Use of NSAIDs

(2013) Alexa Simon Meara et al.   PAIN MEDICINE

Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies

(2013) Cristina Varas-Lorenzo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Cause-Specific Cardiovascular Risk Associated with Nonsteroidal Anti-Inflammatory Drugs among Myocardial Infarction Patients - A Nationwide Study

(2013) Anne-Marie Schjerning Olsen et al.   PLoS One

Glucocorticoid Dose Thresholds Associated With All-Cause and Cardiovascular Mortality in Rheumatoid Arthritis

(2013) Inmaculada del Rincón et al.   Arthritis & Rheumatology

Population-Based Incidence and Prevalence of Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program

(2013) Emily C. Somers et al.   Arthritis & Rheumatology

Comparative effects of non-steroidal anti-inflammatory drugs (NSAIDs) on blood pressure in patients with hypertension

(2012) Hisham Aljadhey et al.   BMC Cardiovascular Disorders

Risk of new acute myocardial infarction hospitalization associated with use of oral and parenteral non-steroidal anti-inflammation drugs (NSAIDs): a case-crossover study of Taiwan's National Health Insurance claims database and review of current evidence

(2012) Wen-Yi Shau et al.   BMC Cardiovascular Disorders

Cardiovascular safety of lumiracoxib: a meta-analysis of randomised controlled trials in patients with osteoarthritis

(2012) Isla S. Mackenzie et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Harmful Effects of NSAIDs among Patients with Hypertension and Coronary Artery Disease

(2011) Anthony A. Bavry et al.   AMERICAN JOURNAL OF MEDICINE

Dose Response Between Physical Activity and Risk of Coronary Heart Disease

(2011) Jacob Sattelmair et al.   CIRCULATION

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

(2011) Thomas J. Schnitzer et al.   CLINICAL RHEUMATOLOGY

Impact of non-steroidal anti-inflammatory drugs (NSAIDs) on cardiovascular outcomes in patients with stable atherothrombosis or multiple risk factors

(2011) Olivier Barthélémy et al.   INTERNATIONAL JOURNAL OF CARDIOLOGY

Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies

(2011) Patricia McGettigan et al.   PLOS MEDICINE

Use of Non-Steroidal Antiinflammatory Drugs and Type-Specific Risk of Acute Coronary Syndrome

(2010) Héctor Bueno et al.   AMERICAN JOURNAL OF CARDIOLOGY

Excess risk of hospital admission for cardiovascular disease within the first 7 years from onset of inflammatory polyarthritis

(2010) J. Franklin et al.   ANNALS OF THE RHEUMATIC DISEASES

Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community

(2010) Arduino A. Mangoni et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Should Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) be Prescribed to the Older Adult?

(2010) Robert L. Barkin et al.   DRUGS & AGING

Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial

(2010) Francis KL Chan et al.   LANCET

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

(2009) M J L Peters et al.   ANNALS OF THE RHEUMATIC DISEASES

Increased Mortality and Cardiovascular Morbidity Associated With Use of Nonsteroidal Anti-inflammatory Drugs in Chronic Heart Failure

(2009) Gunnar H. Gislason et al.   ARCHIVES OF INTERNAL MEDICINE

Atherosclerosis in Rheumatoid Arthritis Versus Diabetes

(2009) Kimon S. Stamatelopoulos et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease

(2009) Christianne L. Roumie et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada

(2009) Cristina Varas-Lorenzo et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation

(2008) V P van Halm et al.   ANNALS OF THE RHEUMATIC DISEASES

Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients

(2008) N J Goodson et al.   ANNALS OF THE RHEUMATIC DISEASES

The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs

(2008) M W van der Linden et al.   ANNALS OF THE RHEUMATIC DISEASES

Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: A nested, case-control study

(2008) Zurab Nadareishvili et al.   ARTHRITIS AND RHEUMATISM

Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups

(2008) Daniel H. Solomon et al.   ARTHRITIS AND RHEUMATISM

What is the harm-benefit ratio of Cox-2 inhibitors?

(2008) T P van Staa et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Effect of inflammation on kidney function and pharmacokinetics of COX-2 selective nonsteroidal anti-inflammatory drugs rofecoxib and meloxicam

(2008) Sam Harirforoosh et al.   JOURNAL OF APPLIED TOXICOLOGY

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs

(2008) Timothy D Warner et al.   LANCET

Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis

(2008) Marianne Cunnington et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Onset of acute myocardial infarction after use of non-steroidal anti-inflammatory drugs

(2008) Tarek A. Hammad et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY